Is Elekta (OM:EKTA B) Below Fair Value As ASTRO 2026 Data Draws Attention?
Elekta (OM:EKTA B) is in focus after a cluster of ASTRO 2026 presentations on Gamma Knife radiosurgery, Unity MR-Linac pancreatic cancer outcomes, and an expanded adaptive radiotherapy portfolio drew fresh clinical attention.
Investors have been reacting to this ASTRO news against a mixed backdrop for Elekta, with the share price at SEK53.3 and a 30-day share price return of 4.1% adding to a 90-day gain of 4.8%. However, the year-to-date share price return is down 6.1%, and the 5-year total shareholder return has declined 34.4%.
Scan beyond Elekta and see which peers are also drawing fresh clinical attention with a hand-picked set of 126 healthcare AI stocks in high-precision, tech-enabled treatment.
Elekta has bounced in the short term but still carries a 5 year total shareholder return that has fallen 34.4%. Has the recent ASTRO optimism reset the story, or has it already captured most of the upside in the valuation ahead?
Most Popular Narrative: 12% Undervalued
Elekta's most followed valuation story points to a fair value of SEK60.5 against the latest close at SEK53.3. This frames ASTRO 2026 interest against a thesis that still leans toward upside in the numbers.
A rising global cancer burden from aging populations, combined with infrastructure growth in emerging markets like India and China, ensures a sustained, long-term demand backdrop for advanced radiotherapy solutions, underpinning a multi-year revenue growth profile for Elekta if current valuation discounts this opportunity.
See why 13 investors see Elekta as 12% undervalued.
Result: Fair Value of SEK60.5 (UNDERVALUED)
Still, the Elekta narrative leans heavily on a China recovery and smoother FDA approvals, and setbacks on either front could quickly cool that ASTRO fueled optimism.
Find out about the key risks to this Elekta narrative.
Next Steps
If this Elekta story feels finely balanced between concern and optimism, consider acting promptly and stress test the full picture by weighing 3 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Elekta?
If Elekta has sharpened your focus on opportunities, do not stop here. Broaden your watchlist now so you are not the one catching up later.
- Target potential value upside by scanning a curated pool of companies that combine quality fundamentals with appealing prices through the 184 high quality undervalued stocks.
- Strengthen your income stream by reviewing established payers in the 170 dividend fortresses that couple higher yields with resilience in their business models.
- Dial down portfolio stress by filtering for sturdier balance sheets using the list of solid balance sheet and fundamentals (206 results) that spotlights companies with robust financial footing.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com